Sentinel node biopsy for the management of early stage endometrial cancer: long-term results of the SENTI-ENDO study.

Détails

ID Serval
serval:BIB_00B62AE73384
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Titre
Sentinel node biopsy for the management of early stage endometrial cancer: long-term results of the SENTI-ENDO study.
Périodique
Gynecologic Oncology
Auteur(s)
Daraï E., Dubernard G., Bats A.S., Heitz D., Mathevet P., Marret H., Querleu D., Golfier F., Leblanc E., Rouzier R., Ballester M.
ISSN
1095-6859 (Electronic)
ISSN-L
0090-8258
Statut éditorial
Publié
Date de publication
2015
Peer-reviewed
Oui
Volume
136
Numéro
1
Pages
54-59
Langue
anglais
Notes
Publication types: Clinical Trial ; Journal Article ; Multicenter Study ; Research Support, Non-U.S. Gov'tPublication Status: ppublish
Résumé
OBJECTIVE: We report the long-term results of the SENTI-ENDO study evaluating the impact of sentinel lymph node (SLN) biopsy on management and survival in patients with early stages of endometrial cancer (EC).
METHODS: Patients with FIGO stage I-II EC underwent pelvic SLN biopsy after cervical dual injection (technetium and patent blue) and systematic pelvic node dissection. This study is a secondary endpoint reporting the long-term recurrence free survival (RFS) and the impact of the SLN procedure on adjuvant therapies.
RESULTS: The median follow-up was 50 months (range: 3-77 months). Eighteen of the 125 patients (14.4%) experienced a recurrence. The 50-month recurrence-free survival (RFS) was 84.7% with no difference between patients with and without detected SLN (p = 0.09). Among patients with detected SLN (111), no difference in RFS was observed between those with and without positive SLN (p = 0.5). In the whole population, adjuvant therapy was performed in low-, intermediate- and high-risk groups in 31 of 64 patients (48.4%), 28 of 37 patients (75.7%) and 14 of 17 patients (82.3%), respectively (p = 0.0001). For the 111 patients with detected SLN, EBRT was performed in 27 of the 89 with negative SLN and in 11 of the 14 with positive SLN (p = 0.001). Chemotherapy was performed more frequently in patients with positive SLN (6/12, 50%) than in patients with negative SLN (7/56, 12.5%) (p = 0.009).
CONCLUSIONS: Our results support the impact of SLN biopsy on surgical management and indications for adjuvant therapies. Further studies are required to assess the clinical impact of the SLN biopsy in early stage EC.
Mots-clé
Adult, Aged, Aged, 80 and over, Chemoradiotherapy, Adjuvant, Chemotherapy, Adjuvant, Disease-Free Survival, Endometrial Neoplasms/drug therapy, Endometrial Neoplasms/pathology, Female, Follow-Up Studies, Humans, Lymph Node Excision, Lymph Nodes/pathology, Lymph Nodes/surgery, Middle Aged, Neoplasm Staging, Prospective Studies, Radiotherapy, Adjuvant, Sentinel Lymph Node Biopsy/methods
Pubmed
Web of science
Création de la notice
16/02/2015 9:38
Dernière modification de la notice
20/08/2019 13:23
Données d'usage